{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:02:16Z","timestamp":1761238936404,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":47,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071618837"},{"type":"electronic","value":"9781071618844"}],"license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1884-4_5","type":"book-chapter","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T16:04:44Z","timestamp":1639670684000},"page":"111-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["mRNA Vaccines to Protect Against Diseases"],"prefix":"10.1007","author":[{"given":"Sunil","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"issue":"4","key":"5_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17(4):261\u2013279","journal-title":"Nat Rev Drug Discov"},{"issue":"4949 Pt 1","key":"5_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1):1465\u20131468","journal-title":"Science"},{"issue":"25","key":"5_CR3","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, T\u00fcreci \u00d6, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, \u015eahin U, Gruber WC (2020) Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 383(25):2439\u20132450","journal-title":"N Engl J Med"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, T\u00fcreci \u00d6, Nell H, Schaefer A, \u00dcnal S, Tresnan DB, Mather S, Dormitzer PR, \u015eahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603\u20132615","journal-title":"N Engl J Med"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NAC Jackson","year":"2020","unstructured":"Jackson NAC, Kester KE, Casimiro D et al (2020) The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines 5:11","journal-title":"npj Vaccines"},{"key":"5_CR6","doi-asserted-by":"publisher","first-page":"571030","DOI":"10.3389\/fmedt.2020.571030","volume":"2","author":"Z Xu","year":"2020","unstructured":"Xu Z, Patel A, Tursi NJ, Zhu X, Muthumani K, Kulp DW, Weiner DB (2020) Harnessing recent advances in synthetic DNA and electroporation Technologies for rapid vaccine development against COVID-19 and other emerging infectious diseases. Front Med Technol 2:571030","journal-title":"Front Med Technol"},{"key":"5_CR7","first-page":"4228","volume":"254","author":"P Atanasiu","year":"1962","unstructured":"Atanasiu P, Orth G, Rebiere JP, Boiron M, Paoletti C (1962) Production of tumors in the hamster by inoculation of desoxyribonucleic acid extracted from tissue cultures infected with polyoma virus. C R Hebd Seances Acad Sci 254:4228\u20134230","journal-title":"C R Hebd Seances Acad Sci"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/356152a0","volume":"356","author":"T Dc","year":"1992","unstructured":"Dc T, DeVit M, Johnston S (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356:152\u2013154","journal-title":"Nature"},{"issue":"5102","key":"5_CR9","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1126\/science.8456302","volume":"259","author":"JB Ulmer","year":"1993","unstructured":"Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A et al (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259(5102):1745\u20131749","journal-title":"Science"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"M Kutzler","year":"2008","unstructured":"Kutzler M, Weiner D (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776\u2013788","journal-title":"Nat Rev Genet"},{"issue":"1","key":"5_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","volume":"239","author":"MA Liu","year":"2011","unstructured":"Liu MA (2011) DNA vaccines: an historical perspective and view to the future. Immunol Rev 239(1):62\u201384","journal-title":"Immunol Rev"},{"issue":"11","key":"5_CR12","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.3390\/ijms19113605","volume":"19","author":"D Hobernik","year":"2018","unstructured":"Hobernik D, Bros M (2018) DNA vaccines-how far from clinical use? Int J Mol Sci 19(11):3605","journal-title":"Int J Mol Sci"},{"issue":"7","key":"5_CR13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/eji.1830230749","volume":"23","author":"F Martinon","year":"1993","unstructured":"Martinon F, Krishnan S, Lenzen G, Magn\u00e9 R, Gomard E, Guillet JG, L\u00e9vy JP, Meulien P (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23(7):1719\u20131722","journal-title":"Eur J Immunol"},{"issue":"1","key":"5_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/2051013613508729","volume":"2","author":"KJ Kallen","year":"2014","unstructured":"Kallen KJ, The\u00df A (2014) A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2(1):10\u201313","journal-title":"Ther Adv Vaccines"},{"issue":"2","key":"5_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3 K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23(2):165\u2013175","journal-title":"Immunity"},{"issue":"11","key":"5_CR16","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833\u20131840","journal-title":"Mol Ther"},{"key":"5_CR17","doi-asserted-by":"crossref","unstructured":"Zeng C, Zhang C, Walker PG, Dong Y (2020) Formulation and delivery technologies for mRNA vaccines. Curr Top Microbiol Immunol","DOI":"10.1007\/82_2020_217"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Maruggi G, Shan H, Li J (2019) Advances in mRNA vaccines for infectious diseases. Front Immunol 10:594","journal-title":"Front Immunol"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D (2015) Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 217:345\u2013351","journal-title":"J Control Release"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.20411\/pai.v5i1.377","volume":"5","author":"S Thomas","year":"2020","unstructured":"Thomas S (2020) The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET. Pathog Immun 5:342\u2013363","journal-title":"Pathog Immun"},{"key":"5_CR21","doi-asserted-by":"crossref","unstructured":"Thomas S (2021) Mapping the non-structural transmembrane proteins of SARS-CoV-2. J Comput Biol (in press)","DOI":"10.20944\/preprints202012.0366.v2"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270\u2013273","journal-title":"Nature"},{"issue":"10","key":"5_CR23","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.mayocp.2020.07.021","volume":"95","author":"GA Poland","year":"2020","unstructured":"Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB (2020) SARS-CoV-2 vaccine development: current status. Mayo Clin Proc 95(10):2172\u20132188","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"5_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat F, Krammer F (2020) SARS-CoV-2 vaccines: status report. Immunity 52(4):583\u2013589","journal-title":"Immunity"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2020.12.011","volume":"170","author":"JY Chung","year":"2020","unstructured":"Chung JY, Thone MN, Kwon YJ (2020) COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev 170:1\u201325","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"5_CR26","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson \u00d6, Thompson J, Ribeiro AM, Watson M, Zaks T, Ciaramella G (2017) Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 25(6):1316\u20131327","journal-title":"Mol Ther"},{"key":"5_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.54","volume":"2","author":"A Hekele","year":"2013","unstructured":"Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A (2013) Rapidly produced SAM(\u00ae) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2:e52","journal-title":"Emerg Microbes Infect"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"B Petsch","year":"2012","unstructured":"Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30:1210\u20131216","journal-title":"Nat Biotechnol"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41541-017-0032-6","volume":"2","author":"J Lutz","year":"2017","unstructured":"Lutz J, Lazzaro S, Habbeddine M, Schmidt KE, Baumhof P, Mui BL, Tam YK, Madden TD, Hope MJ, Heidenreich R, Fotin-Mleczek M (2017) Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2:29","journal-title":"NPJ Vaccines"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3389\/fimmu.2017.01539","volume":"8","author":"G Lindgren","year":"2017","unstructured":"Lindgren G, Ols S, Liang F, Thompson EA, Lin A, Hellgren F, Bahl K, John S, Yuzhakov O, Hassett KJ (2017) Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol 8:1539","journal-title":"Front Immunol"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, Karik\u00f3 K, Barbosa CJ, Madden TD (2018) Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun 9:3361","journal-title":"Nat Commun"},{"issue":"4","key":"5_CR32","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi G, Zhang C, Li J, Ulmer JB, Yu D (2019) mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther 27(4):757\u2013772","journal-title":"Mol Ther"},{"key":"5_CR33","unstructured":"WHO (2020) Rabies. Retrieved from: https:\/\/www.who.int\/health-topics\/rabies#tab=tab_1"},{"issue":"4","key":"5_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/vaccines7040132","volume":"7","author":"N Armbruster","year":"2019","unstructured":"Armbruster N, Jasny E, Petsch B (2019) Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies. Vaccine 7(4):132","journal-title":"Vaccine"},{"issue":"10101","key":"5_CR35","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, Fotin-Mleczek M, Hoerr I, Clemens R, von Sonnenburg F (2017) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390(10101):1511\u20131520","journal-title":"Lancet"},{"issue":"8","key":"5_CR36","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","volume":"39","author":"C Aldrich","year":"2021","unstructured":"Aldrich C, Leroux-Roels I, Huang KB, Bica MA, Loeliger E, Schoenborn-Kellenberger O, Walz L, Leroux-Roels G, von Sonnenburg F, Oostvogels L (2021) Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine 39(8):1310\u20131318","journal-title":"Vaccine"},{"key":"5_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1515\/9781400883257-003","volume-title":"Virus: an illustrated guide to 101 incredible microbes","author":"M Roossinck","year":"2016","unstructured":"Roossinck M, Zimmer C (2016) Human viruses. In: Virus: an illustrated guide to 101 incredible microbes. Princeton University Press, Princeton, pp 50\u201397"},{"issue":"1","key":"5_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.chom.2018.05.021","volume":"24","author":"C Shan","year":"2018","unstructured":"Shan C, Xie X, Shi P (2018) Zika Virus Vaccine: Progress and Challenges. Cell Host Microbe 24(1):12\u201317","journal-title":"Cell Host Microbe"},{"issue":"7644","key":"5_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Weissman D (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543(7644):248\u2013251","journal-title":"Nature"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","volume":"169","author":"JM Richner","year":"2017","unstructured":"Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC (2017) Modified mRNA vaccines protect against Zika virus infection. Cell 169:176","journal-title":"Cell"},{"issue":"2","key":"5_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","volume":"35","author":"G Maruggi","year":"2017","unstructured":"Maruggi G, Chiarot E, Giovani C, Buccato S, Bonacci S, Frigimelica E, Margarit I, Geall A, Bensi G, Maione D (2017) Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35(2):361\u2013368","journal-title":"Vaccine"},{"issue":"1","key":"5_CR42","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1038\/s41467-018-05041-7","volume":"9","author":"A Baeza Garcia","year":"2018","unstructured":"Baeza Garcia A, Siu E, Sun T, Exler V, Brito L, Hekele A, Otten G, Augustijn K, Janse CJ, Ulmer JB, Bernhagen J, Fikrig E, Geall A, Bucala R (2018) Neutralization of the plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat Commun 9(1):2714","journal-title":"Nat Commun"},{"key":"5_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-319-42934-2_5","volume":"209","author":"K Fiedler","year":"2016","unstructured":"Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R (2016) mRNA cancer vaccines. Recent Results Cancer Res 209:61\u201385","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"5_CR44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","volume":"26","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang L, Xu Z, Miao L, Huang L (2018) mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma. Mol Ther 26(2):420\u2013434","journal-title":"Mol Ther"},{"issue":"39","key":"5_CR45","doi-asserted-by":"publisher","first-page":"E9153","DOI":"10.1073\/pnas.1810002115","volume":"115","author":"OAW Haabeth","year":"2018","unstructured":"Haabeth OAW, Blake TR, McKinlay CJ, Waymouth RM, Wender PA, Levy R (2018) mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A 115(39):E9153\u2013E9161","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"794528","DOI":"10.1155\/2015\/794528","volume":"2015","author":"MA McNamara","year":"2015","unstructured":"McNamara MA, Nair SK, Holl EK (2015) RNA-based vaccines in cancer immunotherapy. J Immunol Res 2015:794528","journal-title":"J Immunol Res"},{"key":"5_CR47","volume-title":"Pioneers in science: Katalin Karik\u00f3. Advanced science news","author":"A Brown","year":"2021","unstructured":"Brown A (2021) Pioneers in science: Katalin Karik\u00f3. Advanced science news. Retrieved from: https:\/\/www.advancedsciencenews.com\/pioneers-in-science-katalin-kariko\/"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1884-4_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T08:15:56Z","timestamp":1666685756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1884-4_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"ISBN":["9781071618837","9781071618844"],"references-count":47,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1884-4_5","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"17 December 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}